How does the Tel-Aviv Stock Exchange (TASE) compare to the NASDAQ, AMEX, and other U.S. exchanges? What is the rationale for U.S. biomed investors to look at TASE-listed companies? What are the benefits of a dual U.S.-TASE listing? With a strong culture of innovation and entrepreneurship, 51 TASE-listed biomed companies, and hundreds more in earlier stages, it would make logical sense for U.S. biomed investors to consider Israeli biomed companies. Ester Levanon, CEO of the Tel-Aviv Stock Exchange discusses the opportunities presented by the TASE as well as the challenges still to be overcome (e.g. achieving increased analyst coverage and increasing liquidity).
This interview was conducted at the NASDAQ Marketsite, on December 6th, 2010, in New York City.
Featuring:
Related Videos: